Results 191 to 200 of about 5,876,256 (302)

Discocelia Plataet Sp. n., a Small Incertae Sedis Cercozoan Flagellate. [PDF]

J Eukaryot Microbiol
Prokina K, Torruella G, Galindo LJ, Dudin O, López-García P, Moreira D.   +5 more
europepmc   +1 more source

Улога на метаболичниот Ñиндром во развој и прогреÑија на хроничната бубрежна ÑлабоÑÑ‚

, 2015
Tatjana Barjaktarova Prosheva, Лилјана Тозија   +1 more
openalex  

Ð Ð¾Ð²Ð¸Ñ Ñ‚ Международен Ñ Ñ‚Ð°Ð½Ð´Ð°Ñ€Ñ‚ за Ñ„Ð¸Ð½Ð°Ð½Ñ Ð¾Ð²Ð¾ отчитане 17 и Ð¿Ñ€ÐµÐ´Ð¸Ð·Ð²Ð¸ÐºÐ°Ñ‚ÐµÐ»Ñ Ñ‚Ð²Ð°Ñ‚Ð° пред Ð·Ð°Ñ Ñ‚Ñ€Ð°Ñ…Ð¾Ð²Ð°Ñ‚ÐµÐ»Ð½Ð¸Ñ‚Ðµ компании [PDF]

, 2020
Ð Ð ÐμÐ ⁄ Ð ⁄ Ð ⁄ ра СтаР⁄ чÐμРа-ТР⁄ Ð ́Ð ⁄ рР⁄ Ра, РаР́Ñ Ð’ÐμÐ Ð ̧Ð ⁄ Ð ⁄ Ра-СР⁄ ÐoÐ ⁄ Ð Ð ⁄ Ра   +1 more
openalex  

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. [PDF]

Clin Cancer Res
Grierson PM, Wolf C, Suresh R, Wang-Gillam A, Tan BR, Ratner L, Oppelt P, Aranha O, Frith A, Pedersen KS, Spann J, Boice N, Brown A, Baer JM, Butka EG, Ahmad F, Xu Y, Liu J, DeNardo DG, Lim KH.   +19 more
europepmc   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study. [PDF]

Cancer Med
Russo I, Di Ruscio V, De Ioris MA, Del Baldo G, De Pasquale MD, Valente P, Opocher E, Parrozzani R, Di Giannatale A, Cefalo MG, Serra A, Milano GM, Longo D, Carboni A, De Vito R, Natali G, D'Elia G, Bisogno G, Mastronuzzi A, Cozza R, Alaggio R, Romanzo A, Buzzonetti L, Locatelli F.   +23 more
europepmc   +1 more source

Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology

Molecular Oncology, EarlyView.
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban, Shivakumar Keerthikumar, Ashlee Clark, Hong Wang, Belinda Phipson, Andrew Bakshi, Andrew Ryan, Heather Thorne, Renea A. Taylor, Mitchell G. Lawrence, Gail P. Risbridger, Roxanne Toivanen, David L. Goode   +12 more
wiley   +1 more source

Differential Astrocyte-Supplied NMDAR Co-Agonist for CA1 Versus Dentate Gyrus Long-Term Potentiation. [PDF]

Hippocampus
Sateesh S, Abraham WC.
europepmc   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source